{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:03:41Z","timestamp":1740107021026,"version":"3.37.3"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00520-024-09024-x","type":"journal-article","created":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T12:36:12Z","timestamp":1732192572000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["KRAS-G12 inhibitors in lung cancer therapy: unveiling the toxicity profile through a pharmacovigilance study"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5285-8939","authenticated-orcid":false,"given":"Wenjie","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8887-8499","authenticated-orcid":false,"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,21]]},"reference":[{"issue":"9","key":"9024_CR1","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.annonc.2021.06.001","volume":"32","author":"M Reck","year":"2021","unstructured":"Reck M, Carbone D, Garassino M, Barlesi F (2021) Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches. Ann Oncol 32(9):1101\u20131110","journal-title":"Ann Oncol"},{"issue":"13","key":"9024_CR2","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","volume":"383","author":"D Hong","year":"2020","unstructured":"Hong D, Fakih M, Strickler J, Desai J, Durm G, Shapiro G, Falchook G, Price T, Sacher A, Denlinger C et al (2020) KRAS inhibition with sotorasib in advanced solid tumors. N Engl J Med 383(13):1207\u20131217","journal-title":"N Engl J Med"},{"issue":"10378","key":"9024_CR3","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","volume":"401","author":"A de Langen","year":"2023","unstructured":"de Langen A, Johnson M, Mazieres J, Dingemans A, Mountzios G, Pless M, Wolf J, Schuler M, Lena H, Skoulidis F et al (2023) Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS mutation: a randomised, open-label, phase 3 trial. Lancet 401(10378):733\u2013746","journal-title":"Lancet"},{"issue":"23","key":"9024_CR4","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1056\/NEJMoa2308795","volume":"389","author":"MG Fakih","year":"2023","unstructured":"Fakih MG, Salvatore L, Esaki T, Modest DP, Lopez-Bravo DP, Taieb J, Karamouzis MV, Ruiz-Garcia E, Kim T-W, Kuboki Y et al (2023) Sotorasib plus panitumumab in refractory colorectal cancer with mutated KRAS G12C. N Engl J Med 389(23):2125\u20132139","journal-title":"N Engl J Med"},{"issue":"25","key":"9024_CR5","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","volume":"384","author":"F Skoulidis","year":"2021","unstructured":"Skoulidis F, Li BT, Dy GK, Price TJ, Falchook GS, Wolf J, Italiano A, Schuler M, Borghaei H, Barlesi F et al (2021) Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med 384(25):2371\u20132381","journal-title":"N Engl J Med"},{"issue":"10378","key":"9024_CR6","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","volume":"401","author":"AJ de Langen","year":"2023","unstructured":"de Langen AJ, Johnson ML, Mazieres J, Dingemans AC, Mountzios G, Pless M, Wolf J, Schuler M, Lena H, Skoulidis F et al (2023) Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase 3 trial. Lancet 401(10378):733\u2013746","journal-title":"Lancet"},{"issue":"7","key":"9024_CR7","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2165\/00002018-200730070-00011","volume":"30","author":"A Bate","year":"2007","unstructured":"Bate A (2007) Bayesian confidence propagation neural network. Drug Saf 30(7):623\u2013625","journal-title":"Drug Saf"},{"issue":"7","key":"9024_CR8","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, Okuno Y (2013) Data mining of the public version of the FDA Adverse Event Reporting System. Int J Med Sci 10(7):796\u2013803","journal-title":"Int J Med Sci"},{"issue":"6","key":"9024_CR9","doi-asserted-by":"publisher","first-page":"485","DOI":"10.2217\/pme-2023-0072","volume":"20","author":"W Li","year":"2023","unstructured":"Li W, Wen K, Zhu W, Luo S (2023) A real-world analysis of tyrosine receptor kinase inhibitor-related toxicities in cancer treatment. Pers Med 20(6):485\u2013491","journal-title":"Pers Med"},{"key":"9024_CR10","doi-asserted-by":"publisher","unstructured":"Wenjie Li, Ruxue Lv, Wei Wang (2024) Toxicity profiles associated with EGFR-TKIs combined with angiogenesis inhibitors in non-small cell lung cancer: an epidemiological surveillance analysis of the FDA adverse event reporting system. Expert Opin Drug Saf pp 1\u201310. https:\/\/doi.org\/10.1080\/14740338.2024.2399082","DOI":"10.1080\/14740338.2024.2399082"},{"issue":"15","key":"9024_CR11","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.2217\/fon-2022-1106","volume":"19","author":"MZ Guo","year":"2023","unstructured":"Guo MZ, Marrone KA, Spira A, Rosner S (2023) Adagrasib: a novel inhibitor for KRAS G12C-mutated non-small-cell lung cancer. Future Oncol 19(15):1037\u20131051","journal-title":"Future Oncol"},{"issue":"4","key":"9024_CR12","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1093\/oncolo\/oyad051","volume":"28","author":"J Zhang","year":"2023","unstructured":"Zhang J, Johnson M, Barve M, Bazhenova L, McCarthy M, Schwartz R, Horvath-Walsh E, Velastegui K, Qian C, Spira A (2023) Practical guidance for the management of adverse events in patients with KRASG12C-mutated non-small cell lung cancer receiving adagrasib. Oncologist 28(4):287\u2013296","journal-title":"Oncologist"},{"key":"9024_CR13","doi-asserted-by":"publisher","unstructured":"Wei Luo, Jing Zhu, Wenxue Zhang, Airu Yu, Wei Zhou, Ke Xu (2023) Efficacy and toxicity of drugs targeting KRAS(G12C) mutation in non-small cell lung cancer: a meta-analysis. Expert Rev Anticancer Ther 23(12):1295\u20131303. https:\/\/doi.org\/10.1080\/14737140.2023.2282606","DOI":"10.1080\/14737140.2023.2282606"},{"key":"9024_CR14","doi-asserted-by":"publisher","first-page":"1380584","DOI":"10.3389\/fonc.2024.1380584","volume":"14","author":"H Miyashita","year":"2024","unstructured":"Miyashita H, Kato S, Hong DS (2024) KRAS G12C inhibitor combination therapies: current evidence and challenge. Front Oncol 14:1380584","journal-title":"Front Oncol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-09024-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-024-09024-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-09024-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T04:18:02Z","timestamp":1733717882000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-024-09024-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,21]]},"references-count":14,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["9024"],"URL":"https:\/\/doi.org\/10.1007\/s00520-024-09024-x","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2024,11,21]]},"assertion":[{"value":"20 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethics approval and written consent were needed for the secondary analysis of public data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"812"}}